Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 454-462

  Blitz, Sandra ^a   Baxter, Joanna ^e,f   Raboud, Janet ^a,b   Walmsley, Sharon ^a,c   Rachlis, Anita ^c,d   Smaill, Fiona ^g   Ferenczy, Alex ^h,i   Coutlée, François ^j,l   Hankins, Catherine ^k,m,n,o   Money, Deborah ^e,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canada   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f BC Women's Hospital   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j Département de Microbiologie et Infectiologie   (Canada)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^m Department of Global Health   (Canada)

ⁿ UNIVERSITY OF AMSTERDAM   (Netherlands)

^o LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

cervical cancer; cervical dysplasia; cervical squamous intraepithelial lesion; HAART; HIV; HPV; women

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CERVICAL SQUAMOUS INTRAEPITHELIAL LESION; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REMISSION; SEXUAL BEHAVIOR; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; UTERINE CERVIX DYSPLASIA; VIRAL CLEARANCE; WOMEN'S HEALTH;

CERVICAL CANCER; CERVICAL DYSPLASIA; CERVICAL SQUAMOUS INTRAEPITHELIAL LESION; HAART; HIV; HPV; WOMEN;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; CYTOLOGICAL TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 84880242370     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit181     Document Type: Article

References (40)

1. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squa-mous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-7.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillo-mavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
5. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8.
6. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32.
7. Coutlee F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83:1034-41.
8. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 2003; 169:431-4.
9. Adler DH. The Impact of HAART on HPV-related Cervical Disease. Curr HIV Res 2010; 8:493-7.
10. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998; 178:982-6.
11. Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070-6.
12. Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ 1999; 160:185-91.
13. Hankins C, Coutlee F, Girard M, Pourreaux K, Lapointe N, the Canadian Women's HIV Study Group. Immunosuppression and contraceptive practices associated with persistence of human papillomavirus in HIV-positive and HIV-negative women. Presented at: XIIIth International AIDS Conference, Durban, South Africa, 9-14 July 2000 (Abstract MoOrB235).
14. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of highgrade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188:555-63.
15. Conti M, Agarossi A, Parazzini F, et al. HPV, HIV-infection, and risk of cervical intraepithelial neoplasia in former intravenous drug-abusers. Gynecol Oncol 1993; 49:344-8.
16. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIVpositive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 2004; 25:689-98.
17. Marais DJ, Passmore JAS, Denny L, Sampson C, Allan BR, Williamson AL. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in south Africa. J Med Virol 2008; 80:953-9.
18. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999; 21(Suppl 1):S42-8.
19. Luque AE, Jabeen M, Messing S, et al. Prevalence of human papilloma-virus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006; 194:428-34.
20. Clifford GM, Goncalves MAG, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337-44.
21. McKenzie ND, Kobetz EN, Hnatyszyn J, Twiggs LB, Lucci JA. Women with HIV are more commonly infected with non-16 and-18 high-risk HPV types. Gynecol Oncol 2010; 116:572-7.
22. Koshiol JE, Schroeder JC, Jamieson DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006; 119:1623-9.
23. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-71.
24. Firnhaber C, Van Le H, Pettifor A, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 2010; 21:433-43.
25. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 2000; 96:403-9.
26. Levi JE, Fernandes S, Tateno AF, et al. Presence of multiple human pap-illomavirus types in cervical samples from HIV-infected women. Gynecol Oncol 2004; 92:225-31.
27. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-36.
28. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of Human Papillomavirus-Associated Cancers Among Persons With AIDS. J Natl Cancer Inst 2009; 101:1120-30.
29. Shrestha S, Bachmann LH, Wilson CM, Kempf MC. Pre-and postHAART prevalence, incidence, and type-specific HPV persistence among HIV-positive adolescents. Presented at: 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 17-20 August 2008 (Abstract 478).
30. Broder S. The bethesda system for reporting cervical vaginal cytologic diagnoses-report of the 1991 Bethesda workshop. JAMA 1992; 267:1892.
31. Coutlee F, Hankins C, Lapointe N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. J Med Virol 1997; 51:42-7.
32. Coutlee F, Gravitt P, Richardson H, et al. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group. J Clin Microbiol 1999; 37:1852-7.
33. Cox D, Miller H. The theory of stochastic processes. London: Chapman and Hall, 1965.
34. Kalbfleisch JD, Lawless JF. The analysis of panel data under a Markov assumption. Journal of the American Statistical Association 1985; 80:863-71.
35. Jackson CH, Sharples LD, Thompson SG, Duffy SW, Couto E. Multistate Markov models for disease progression with classification error. Journal of the Royal Statistical Society Series D-the Statistician 2003; 52:193-209.
36. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13-22.
37. Paramsothy P, Jamieson DJ, Heilig CM, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26-31.
38. Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:274-82.
39. Saint-Pierre P, Combescure C, Daures JP, Godard P. The analysis of asthma control under a Markov assumption with use of covariates. Stat Med 2003; 22:3755-70.
40. Kang M, Lagakos SW. Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics 2007; 8:252-64.